Cergutuzumab Amunaleukin manufacturers
- Cergutuzumab amunaleukin
-
- $893.00
-
2026-07-27
- CAS:1509916-03-3
- Purity: 98% (SDS-PAGE); 99.7% (SEC-HPLC)
- Supply Ability: 10g
|
| | Cergutuzumab Amunaleukin Basic information |
| Product Name: | Cergutuzumab Amunaleukin | | Synonyms: | Cergutuzumab Amunaleukin;Research Grade Cergutuzumab (DHC21002);Research Grade Cergutuzumab;Cergutuzumab;Cergutuzumab (anti-CEACAM5) | | CAS: | 1509916-03-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Cergutuzumab Amunaleukin Structure]() |
| | Cergutuzumab Amunaleukin Chemical Properties |
| form | Liquid | | color | Colorless to off-white |
| | Cergutuzumab Amunaleukin Usage And Synthesis |
| Uses | Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities[1]. | | in vivo | In tumor-free mice, a strong expansion of peripheral CD8+ T and NK cells after treatment with 0.5 and 2 mg/kg Cergutuzumab amunaleukin (CEA-IL2v; i.v.; once) is observed[1]. | | References | [1] Christian Klein, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017 Jan 11;6(3):e1277306. DOI:10.1080/2162402X.2016.1277306 |
| | Cergutuzumab Amunaleukin Preparation Products And Raw materials |
|